Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 20 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q2 2022
Institutional positions in Pharvaris N.V. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −2 vs. Q1 2022
- Shares held
- 22.4M
- +668.0K (+3.1%) vs. Q1 2022
- Total value
- $494.0M
- +$96.9M (+24.4%) vs. Q1 2022
- New holders
- 1
- 7 more added
- Sold out
- 3
- 6 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 125 | $2.23B |
| Q1 2026 | 110 | $1.67B |
| Q4 2025 | 106 | $1.64B |
| Q3 2025 | 83 | $1.44B |
| Q2 2025 | 60 | $792.7M |
| Q1 2025 | 52 | $705.5M |
| Q4 2024 | 54 | $855.8M |
| Q3 2024 | 51 | $834.2M |
| Q2 2024 | 36 | $808.6M |
| Q1 2024 | 35 | $980.5M |
| Q4 2023 | 36 | $1.14B |
| Q3 2023 | 21 | $606.6M |
| Q2 2023 | 21 | $441.6M |
| Q1 2023 | 21 | $173.9M |
| Q4 2022 | 25 | $239.6M |
| Q3 2022 | 21 | $173.6M |
| Q2 2022 | 20 | $494.0M |
| Q1 2022 | 22 | $397.1M |
| Q4 2021 | 22 | $321.1M |
| Q3 2021 | 25 | $380.3M |
| Q2 2021 | 28 | $406.3M |
| Q1 2021 | 33 | $616.5M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Pharvaris N.V.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 3,315,188 | $73.3M | 0.01% | 00.0% | Unchanged |
| Foresite Capital Management IV, LLC | 3,246,926 | $71.8M | 19.32% | −15,000−0.5% | Reduced |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $70.3M | 8.24% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 2,491,923 | $55.1M | 0.25% | +11,604+0.5% | Added |
| General Atlantic LLC | 2,420,155 | $53.5M | 0.70% | 00.0% | Unchanged |
| venBio Partners LLC | 2,301,451 | $50.9M | 14.48% | −1,859−0.1% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 1,190,343 | $26.3M | 0.55% | −386,735−24.5% | Reduced |
| Cormorant Asset Management, LP | 1,145,953 | $25.3M | 1.96% | +461,065+67.3% | Added |
| Suvretta Capital Management, LLC | 827,540 | $18.3M | 0.70% | 00.0% | Unchanged |
| 5AM Venture Management, LLC | 587,600 | $13.0M | 3.21% | +587,600 | New |
| Novo Holdings A/S | 519,339 | $11.5M | 0.57% | +3,018+0.6% | Added |
| Pictet Asset Management SA | 462,630 | $10.2M | 0.01% | −75,000−14.0% | Reduced |
| Eventide Asset Management, LLC | 450,251 | $9.95M | 0.21% | +147,632+48.8% | Added |
| Millennium Management LLC | 81,954 | $1.81M | 0.00% | −26,432−24.4% | Reduced |
| Goldman Sachs Group Inc | 56,951 | $1.26M | 0.00% | +1,115+2.0% | Added |
| Foresite Capital Management V, LLC | 34,142 | $755.0K | 0.53% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 18,643 | $412.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 16,816 | $372.0K | 0.00% | +631+3.9% | Added |
| Bank of America Corp | 4,133 | $91.0K | 0.00% | −1,639−28.4% | Reduced |
| UBS Group AG | 799 | $18.0K | 0.00% | +71+9.8% | Added |
| DAFNA Capital Management LLC | 0 | $0 | 0.00% | −34,615−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −3,429−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −77−100.0% | Sold out |